Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Vivoryon Therapeutics   /   Vivoryon in 2024: Overname, Deal of Down the Drain?

Aandeel VIVORYON THERAPEUTICS N.V. AEX:VVY.NL, NL00150002Q7

Laatste koers (eur) Verschil Volume
1,974   0,000   (0,00%) Dagrange 1,958 - 2,010 117.930   Gem. (3M) 227K

Vivoryon in 2024: Overname, Deal of Down the Drain?

Volgen
2.798 Posts
Pagina: «« 1 ... 42 43 44 45 46 ... 140 »» | Laatste | Omlaag ↓
  8. forum rang 10 DeZwarteRidder 21 mei 2024 12:15
    quote:

    Strateeg schreef op 21 mei 2024 11:07:

    en toch denk ik dat de knal van Euro 8,-- in 1 dag naar penny stock een overdreven reactie was.
    De meningen zijn vooral negatief op dit aandeel, een klein lichtpuntje kan al voor een enorme stijging zorgen.
    We gaan het donderdag zien.
    Donderdag wordt een teleurstelling.
  9. forum rang 4 Rechterzijde 22 mei 2024 11:51
    quote:

    Strateeg schreef op 21 mei 2024 11:07:

    en toch denk ik dat de knal van Euro 8,-- in 1 dag naar penny stock een overdreven reactie was.
    De meningen zijn vooral negatief op dit aandeel, een klein lichtpuntje kan al voor een enorme stijging zorgen.
    We gaan het donderdag zien.
    Zeker, ik ben gisteren ingestapt met een bescheiden aantal aandelen. Die gaan op de plank.
  14. forum rang 10 DeZwarteRidder 23 mei 2024 07:15
    Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease

    Additional kidney function analyses strongly support Vivoryon’s shift in strategic focus to inflammatory and fibrotic diseases, and are a further step towards securing Company’s future

    Varoglutamstat`s beneficial effect of improving kidney function, as demonstrated by an increase of estimated glomerular filtration rate (eGFR), confirmed by various sensitivity and subgroup analyses

    A significant and dose dependent reduction of the pyroglutamated version of CCL2 (pE-CCL2) in serum demonstrates effectiveness of varoglutamstat in inhibiting systemic intracellular QPCT/L and strongly supports an anti-inflammatory effect

    Alzheimer’s disease: No consistent effect on cognition could be shown in a subgroup of VIVIAD participants with higher drug exposure; VIVA-MIND topline results available end 2024 to inform next steps in AD

    Halle (Saale) / Munich, Germany, May 23, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced financial results for the first quarter of 2024, ending March 31, 2024, and provides a corporate update.

    “Vivoryon has now achieved proof of concept for varoglutamstat and validated the mechanism of action of QPCT/L inhibition. While the results in early AD were not what we had hoped for, we are excited about the promising effect of varoglutamstat on the pre-specified endpoint of kidney function given the established role of pro-inflammatory cytokines and peptides in driving the progression of kidney disease. In the past weeks, our team, which remains highly dedicated to driving our strategic shift and transformation, has continued to delve into the data on kidney function and we are pleased to see consistent results. We have observed robust and meaningful improvements in eGFR in patients treated with varoglutamstat compared to placebo across a range of different methods assessing eGFR. Effect sizes in favor of varoglutamstat were confirmed in patients with risk factors for CKD including diabetes and hypertension and were observed consistently across the range of eGFR baseline impairment levels in the study. We are now working on crystallizing our strategy and positioning in the kidney disease market and establishing potential clinical development plans for varoglutamstat in both large indications, such as CKD, and in certain rare diseases that impact kidney function,” said Frank Weber, MD, CEO of Vivoryon.

    Q1 2024 and Post-Period Updates

    Strategic shift towards a focus on inflammatory and fibrotic diseases:

    Following the announcement on March 4, 2024, that the VIVIAD Phase 2b study did not achieve its primary and key secondary endpoints in early AD and the subsequent results showing a significant positive effect of varoglutamstat on kidney function, Vivoryon announced on April 24, 2024, a strategic shift towards a focus on inflammatory and fibrotic diseases. Key priorities now include: exploring varoglutamstat’s potential in inflammatory and fibrotic disorders, including of the kidney; concluding VIVIAD Phase 2b clinical study program and in-depth analysis; discontinuing VIVA-MIND clinical Phase 2 study with varoglutamstat in the U.S. in early AD in the second half of 2024; leveraging the data from VIVA-MIND to inform next steps in AD; and continuing to actively pursue potential business development and financing opportunities.

    Varoglutamstat – kidney disease:

    QPCT/L inhibition has shown robust evidence of benefits in animal models of inflammatory and fibrotic disorders such as glomerulonephritis and non-alcoholic steatohepatitis (NASH). The VIVIAD protocol prospectively specified measurement of kidney function by estimated glomerular filtration rate (eGFR), a primary endpoint in many development programs of kidney disorders, and additional biomarkers, in order to further investigate this potential activity.
    Varoglutamstat 600mg BID increased eGFR over the treatment period up to 96 weeks in patients with early AD, indicating a potential benefit of varoglutamstat on kidney function.
    Further sensitivity and subgroup analysis has shown this effect is observed across the range of eGFR levels at baseline in the study, and when assessed using a set of diverse and validated methods for calculating kidney function.
    Additionally, the Company has explored the effect of varoglutamstat on levels of pyroglu-CCL2 (pE-CCL2), a pro-inflammatory cytokine. Persistent, low grade inflammation is considered a hallmark feature of chronic kidney disease (CKD). Results showed a significant and dose-dependent reduction in pE-CCL2 in the serum of VIVIAD patients following treatment with varoglutamstat. This demonstrates the effectiveness of varoglutamstat in inhibiting systemic intracellular QPCT/L and strongly supports an anti-inflammatory effect.
    Vivoryon is evaluating a clinical development path, as well as business development and financing opportunities, to further explore the potential of varoglutamstat and QPCT/L inhibitors in kidney disease in both large indications, such as CKD, and in certain rare diseases that impact kidney function, such as Alport Syndrome.
  15. forum rang 10 DeZwarteRidder 23 mei 2024 07:15
    Varoglutamstat – early Alzheimer’s disease (AD):

    In recent weeks Vivoryon has continued its in-depth analysis of the VIVIAD data, following the March 4, 2024, and April 24, 2024, disclosures. While these analyses remain ongoing, findings to date continue to confirm there is no consistent effect of varoglutamstat up to 600mg BID on cognition and function, including in high exposure patients. Data from VIVA-MIND, anticipated by the end of 2024, is expected to contribute to the overall dataset informing varoglutamstat’s development strategy in AD.

    Early-Stage Pipeline

    Vivoryon’s main focus is on its clinical-stage activities, however it will continue to explore pre-clinical QPCT/L inhibitors for use in inflammatory and fibrotic disorders and other indications such as oncology and CNS as well as pre-clinical meprin inhibitors, in particular for fibrotic disorders, and QPCT/L inhibitors with good blood brain barrier penetration. The Company’s antibody program, PBD-C06, will remain active as a candidate for further potential partnering opportunities.

    Corporate Development Updates

    In March 2024, Kugan Sathiyanandarajah and Professor Dr. Morten Asser Karsdal stepped down from Vivoryon’s Board of Directors. They had been appointed as Non-Executive Directors in June 2023.
    In March 2024, Anne Doering, CFA, assumed the role of Chief Financial Officer (CFO) of Vivoryon, following her previous position as Chief Strategy & Investor Relations Officer.
    In May 2024, Vivoryon announced it will hold its 2024 Annual General Meeting on Friday, June 21, 2024, at 1:00 p.m. (CEST) in Amsterdam, the Netherlands. The full agenda and all relevant documents are available on the Company’s website (https://www.vivoryon.com/2024-annual-general-meeting/).

    Financial Results for the First Quarter of 2024

    Revenues were zero in the three months ended March 31, 2024, as well as in the three months ended March 31, 2023.

    Research and development expenses increased by EUR 4.3 million to EUR 7.4 million in the three months ended March 31, 2024, compared to EUR 3.1 million in the three months ended March 31, 2023. This increase was largely attributable to the increase in clinical development costs from the VIVIAD and VIVA-MIND studies.

    General and administrative expenses were EUR 2.1 million in the three months ended March 31, 2024, compared to EUR 1.9 million in the three months ended March 31, 2023. The increase of EUR 0.2 million was largely attributable to higher expenses for share-based payments as well as legal and consulting fees.

    Net loss for the three months ended March 31, 2024, was EUR 9.3 million, compared to EUR 5.1 million for the three months ended March 31, 2023.

    The Company held EUR 22.0 million in cash and cash equivalents as of March 31, 2024, compared to EUR 28.6 million, which includes cash and cash equivalents and financial assets, as of December 31, 2023.

    Outlook & Financial Guidance

    As published on April 24, 2024, the Company expects, on the basis of its most recent financial and business plan, that its existing cash and cash equivalents will be sufficient to fund its operating plans, excluding any additional financings, into the second quarter of 2025.

    This cash runway guidance reflects the shift in focus of research and development resources towards inflammatory and fibrotic disorders, such as of the kidney, and an overall reduction in cash utilization including the ramp down of spending on VIVIAD as it approaches its conclusion, the discontinuation of VIVA-MIND, the discontinuation of VIVALONG preparation activities given the developments of VIVIAD and VIVA-MIND, as well as the streamlining of manufacturing costs and programs for API development.

    The viability of the Company beyond the second quarter of 2025 is dependent on its ability to raise additional funds to finance its operations which also depends on the success of its research and development activities such as those focusing on exploring opportunities in kidney disease.
  17. forum rang 10 DeZwarteRidder 23 mei 2024 07:23
    Primary analysis of change of estimated glomerular filtration rate (eGFR, slope analysis including all measurement timepoints during treatment):
    Annualized change of eGFR* P-Value Annualized Change of eGFR* P-Value
    Formula (creatinine) MDRD CKD-EPI 2021
    Placebo -1.51 -0.75
    Varoglutamstat +1.92 +1.44
    Treatment Effect (?) 3.43 p=0.0002 2.19 p=0.0015

    * mL/min/1.73m2/year

    Sensitivity analysis of estimated glomerular filtration (eGFR) rate using Cystatin C and Creatinine (remeasured on Atellica® platform) CKD-EPI 2021 formula at baseline, week 24 and week 48:
    Cystatin C Cystatin C and Creatinine Creatinine
    Week 24 Week 48 Week 24 Week 48 Week 24 Week 48
    Placebo
    (eGFR mL/min) 73.88 71.39 84.15 82.07 89.74 88.74
    Varoglutamstat
    (eGFR mL/min) 78.15 80.88 88.91 91.21 93.33 93.98
    Treatment Effect* (?) 4.27 9.49 4.76 9.14 3.59 5.24
    P-Value 0.0186 <0.0001 0.0041 <0.0001 0.0019 0.0003
  18. forum rang 10 DeZwarteRidder 23 mei 2024 07:25
    quote:

    DeZwarteRidder schreef op 23 mei 2024 07:23:

    Primary analysis of change of estimated glomerular filtration rate (eGFR, slope analysis including all measurement timepoints during treatment):
    Annualized change of eGFR* P-Value Annualized Change of eGFR* P-Value
    Formula (creatinine) MDRD CKD-EPI 2021
    Placebo -1.51 -0.75
    Varoglutamstat +1.92 +1.44
    Treatment Effect (?) 3.43 p=0.0002 2.19 p=0.0015

    * mL/min/1.73m2/year

    Sensitivity analysis of estimated glomerular filtration (eGFR) rate using Cystatin C and Creatinine (remeasured on Atellica® platform) CKD-EPI 2021 formula at baseline, week 24 and week 48:
    Cystatin C Cystatin C and Creatinine Creatinine
    Week 24 Week 48 Week 24 Week 48 Week 24 Week 48
    Placebo
    (eGFR mL/min) 73.88 71.39 84.15 82.07 89.74 88.74
    Varoglutamstat
    (eGFR mL/min) 78.15 80.88 88.91 91.21 93.33 93.98
    Treatment Effect* (?) 4.27 9.49 4.76 9.14 3.59 5.24
    P-Value 0.0186 <0.0001 0.0041 <0.0001 0.0019 0.0003
    NB: ik zie weinig effect van Varoglutamstat.
  19. forum rang 10 DeZwarteRidder 23 mei 2024 07:30
    Q1 2024 and Post-Period Updates

    Strategic shift towards a focus on inflammatory and fibrotic diseases:

    Following the announcement on March 4, 2024, that the VIVIAD Phase 2b study did not achieve its primary and key secondary endpoints in early AD and the subsequent results showing a significant positive effect of varoglutamstat on kidney function, Vivoryon announced on April 24, 2024, a strategic shift towards a focus on inflammatory and fibrotic diseases. Key priorities now include: exploring varoglutamstat’s potential in inflammatory and fibrotic disorders, including of the kidney; concluding VIVIAD Phase 2b clinical study program and in-depth analysis; discontinuing VIVA-MIND clinical Phase 2 study with varoglutamstat in the U.S. in early AD in the second half of 2024; leveraging the data from VIVA-MIND to inform next steps in AD; and continuing to actively pursue potential business development and financing opportunities.

    Varoglutamstat – kidney disease:

    QPCT/L inhibition has shown robust evidence of benefits in animal models of inflammatory and fibrotic disorders such as glomerulonephritis and non-alcoholic steatohepatitis (NASH). The VIVIAD protocol prospectively specified measurement of kidney function by estimated glomerular filtration rate (eGFR), a primary endpoint in many development programs of kidney disorders, and additional biomarkers, in order to further investigate this potential activity.
    Varoglutamstat 600mg BID increased eGFR over the treatment period up to 96 weeks in patients with early AD, indicating a potential benefit of varoglutamstat on kidney function.
    Further sensitivity and subgroup analysis has shown this effect is observed across the range of eGFR levels at baseline in the study, and when assessed using a set of diverse and validated methods for calculating kidney function.
    Additionally, the Company has explored the effect of varoglutamstat on levels of pyroglu-CCL2 (pE-CCL2), a pro-inflammatory cytokine. Persistent, low grade inflammation is considered a hallmark feature of chronic kidney disease (CKD). Results showed a significant and dose-dependent reduction in pE-CCL2 in the serum of VIVIAD patients following treatment with varoglutamstat. This demonstrates the effectiveness of varoglutamstat in inhibiting systemic intracellular QPCT/L and strongly supports an anti-inflammatory effect.
    Vivoryon is evaluating a clinical development path, as well as business development and financing opportunities, to further explore the potential of varoglutamstat and QPCT/L inhibitors in kidney disease in both large indications, such as CKD, and in certain rare diseases that impact kidney function, such as Alport Syndrome.
  20. forum rang 10 voda 23 mei 2024 07:56
    Vivoryon verlegt focus op nierziekte
    23-mei-2024 07:49

    Na falen bij Alzheimer-middel.

    (ABM FN-Dow Jones) Vivoryon is optimistisch over de potentie van zijn middel varoglutamstat als mogelijk geneesmiddel bij nierziekte en richt zich daarom nu op ontstekings- en fibrotische aandoeningen, in plaats van op Alzheimer. Dat maakte het bedrijf donderdag bekend bij zijn eerstekwartaalcijfers.

    "De resultaten bij vroege Alzheimer waren niet waar we op hoopten, maar we zijn enthousiast over het veelbelovende effect van varuglutamstat op de nierfunctie", stelde CEO Frank Weber. "Vivoryon heeft een proof-of-concept bereikt voor varoglutamstat en het werkingsmechanisme gevalideerd rond inhibitie van QPCT/L", stelde het bedrijf. Dit zou wijzen op een ontstekingsremmende werking.

    Weber sprak van "consistente resultaten" op dit gebied en zei dat het bedrijf nu focust op een mogelijke klinische ontwikkeling van varoglutamstat bij chronische nierziekte en bepaalde zeldzame ziektes die de nierfunctie beïnvloeden.

    De studie naar Alzheimer stopt in de tweede helft van het jaar vervroegd, meldde het bedrijf al eerder. Het bedrijf kijkt nog naar resultaten bij een hogere dosis. In maart bleek dat er een cognitief effect bij Alzheimer-patiënten niet kon worden aangetoond. De aandelenkoers van Vivoryon stortte toen in.

    Vivoryon zag in het eerste kwartaal de kosten voor onderzoek en ontwikkeling stijgen van 3,1 miljoen naar 7,4 miljoen euro. Het nettoverlies steeg van 5,1 miljoen naar 9,3 miljoen euro en de kaspositie daalde van 28,6 miljoen naar 22,0 miljoen euro.

    Zoals al werd gemeld op 24 april is er voldoende geld in kas om tot het tweede kwartaal van 2025 te komen, op basis van de nieuwe plannen met focus op ontstekings- en fibrotische aandoeningen.

    Door: ABM Financial News.

    info@abmfn.nl

    Redactie: +31(0)20 26 28 999
2.798 Posts
Pagina: «« 1 ... 42 43 44 45 46 ... 140 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

VIVORYON THERAPEUTICS N.V. Nieuws

  1. Weekoverzicht: vastgoed uit de gratie, winst voor automotive en chipaandelen
  2. Kaspositie Vivoryon slinkt
  3. Vivoryon presenteert positieve studieresultaten
  4. Vivoryon zoekt financiering voor nierstudie
  5. Medicijn Vivoryon verbetert nierfunctie bij diabetes
  6. Samenstelling AEX blijft ongewijzigd
  7. T&W kleiner in Vivoryon
  8. Slotcall: AEX komt met de schrik vrij en koers Vivoryon explodeert
  9. Slotcall: Wall Street helpt AEX aan nieuw slotrecord én weekwinst
  10. Vivoryon verlegt focus naar nierziekte